STAT+: A Rubius drug derived from red blood cells produces anti-tumor responses — and more questions
Two patients with cancer showed partial tumor shrinkage after infusions of a novel immune-boosting treatment derived from red blood cells, its maker Rubius Therapeutics said Monday.
Rubius said the preliminary results of its early-stage clinical trial provided “clinical validation” of its treatment, called RTX-240. However, the company was unable to show data proving RTX-240 triggered the expected immune system attack against the patients’ tumors, leaving questions about its future unanswered.
Continue to STAT+ to read the full story…
